This work is an important contribution to understanding the role of FGF signaling in the induction of primitive-like cells in a 2D system of human gastrulation. The authors provide compelling evidence ...

TD Cowen analyst Brendan Smith has maintained their bullish stance on DNLI stock, giving a Buy rating on November 1. Brendan Smith has given ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided business highlights. "As ...

A new study published in the journal of Molecular Psychiatry found that heparin medication was linked to a delayed diagnosis ...

REGENXBIO had positive updated long-term results from phase I/II/III CAMPSITE study using RGX-121 for the treatment of ...

HYOGO, Japan I October 31, 2024 I JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) announced the initiation of the first patient dosing in Japan in the Phase I ...

To her disbelief, Sanfillipo Syndrome, had symptoms that her daughter had been experiencing, which she thought were just ...

Children with Sanfilippo syndrome lack a single enzyme necessary to break down and recycle heparan sulfate, a large, complex molecule that is important for cell-cell interactions. When too much ...

Specifically, Sanfilippo makes the body unable to break down a molecule called heparan sulfate — a natural cellular substance usually metabolized and recycled through enzyme action. As a result ...

Previous research demonstrated that the risk of developing Alzheimer’s may be linked to a protein called Apolipoprotein E (ApoE), which interacts with cell surface molecules known as heparan ...

This manuscript reports on the crystal structures of two glycosaminoglycan (GAG) lyases from the PL35 family, along with in vitro enzyme activity assays and comprehensive structure-guided mutagenesis.

Last year, the U.S. Food and Drug Administration approved 55 new drugs. Choosing the right clinical outcome assessments (COAs) is an important part of successfully advancing drug development and ...